In Vitro: IRAK-1-4 Inhibitor I has IC50 greater than the highest concentration tested (10 μM) against a panel of 27 other kinases, including the most closely homologous (outside of the IRAK family) Lck and pp60SRC. Additionally, IRAK-1-4 Inhibitor I does not show any signs of cytotoxicity in a 72 h proliferation assay in HeLa cells (ED50>30 μM). Significant inhibition of IRAK-1 is observed with IRAK-1-4 Inhibitor I (IRAK-1 IC50=0.3 μM)[1]. IRAK-1/4 inhibitor eliminates the LPS-induced increases in Bcl10, NF-κB, and IL-8. IRAK-1/4 mediates LPS-induced IL-8 activation and functions upstream of Bcl10. The LPS-induced increase in Bcl10 declines by 73% (from 5.18±0.22 to 2.36±0.08 ng/mL), and the IL-8 response decline by 60% (from 2.64±0.31 to 1.14±0.08 ng/mL)[2].
Information
CAS No509093-47-4
FormulaC20H21N5O4
Clinical Informationclinicalinformation
PathwayImmunology/Inflammation Protein Tyrosine Kinase/RTK
TargetIRAK IRAK
Specifications
Purity / Grade>98%
Solubility10 mM in DMSO
Smilessmiles
Misc Information
Alternative NamesIRAK-1/4 Inhibitor I
Observed Molecular Weight395.41
related data
Get valuable resources and offers directly to your email.